Incidence and Risk Factors for Eosinophilia and Lung Disease in Biologic‐Exposed Children With Systemic Juvenile Idiopathic Arthritis
Authors' conclusion
Eosinophilia is common in JIA patients using IL-1/IL-6 inhibitors. Severe disease may be associated with eosinophilia and lung disease in systemic JIA.
Study context
- Population
- Juvenile idiopathic arthritis (JIA) patients at one institution exposed to IL-1/IL-6 inhibitors, 1995–2022264 new medication exposures
- Participants
- 75 vs 41
- Exposure
- sJIA vs other JIA, exposed to IL-1/IL-6 inhibitors
- Systemic JIAn = 75
- Other JIAn = 41reference
- Outcome
- Incidence rate of eosinophilia, stratified by medication class
Methodological detailssingle-centre, Cox models
- Single-centre
- Cox models
Main finding
As reported in the abstract
Eosinophilia during IL-1/IL-6 inhibitor use, incidence rate
P = 0.30
Observational data: associations, not effects.
Further findings
Eosinophilia on biologic therapy, pretreatment macrophage activation syndrome (MAS) (sJIA)
| Unadjusted HR (95% CI) | ||
|---|---|---|
| Pretreatment MAS | 3.2 (1.2–8.3) | |
| 0.10.31310Unadjusted hazard ratio (log scale) |
| Outcome | Systemic JIA |
|---|---|
| HLA-DRB1*15 positivity in sJIA with HLA typing (n = 45) | 49% |
Disease flare after eosinophilia
- Switched therapy within 10 weeks of eosinophilia
- 4 of 5
- Continued original therapy
- none
Death attributed to sJIA-lung disease
- Deaths
- 1
Safety
Lung disease among patients with pulmonary evaluations
- Lung disease
- 8 of 25
- All had severe manifestations of sJIA (MAS, ICU stay)
Original publication
Incidence and Risk Factors for Eosinophilia and Lung Disease in Biologic‐Exposed Children With Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). Published 18 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →